Why Do We Have to Use Chemotherapy?
The use of chemotherapy (CT) in localized rectal cancer (LARC) has two aims: first, to improve the local effect of radiotherapy by giving concomitant chemoradiation and second, to decrease systemic relapses by early treatment for occult micrometastatic disease or to shrink bulky local tumours. Neoadjuvant treatment is reserved for locally advanced disease, as defined by pelvic magnetic resonance imaging, a very useful and accurate tool to identify high-risk features for local or systemic relapse . We are going to address why we have to use CT in LARC.
- 2.Rödel C, Liersch T, Hermann R et al (2007) Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer. J Clin Oncol 25:668–674Google Scholar
- 3.Sebarg-Montefiore D, Rutten H, Rullier E et al (2009) Three-year survival results of CORE (capecitabine, oxaliplatin, radiotherapy, and excision) study after postoperative chemotherapy in patients with locally advanced rectal adenocarcinoma. ASCO GI Meeting Abstracts 447Google Scholar
- 6.Dewdney A, Cunningham D, Tabernero J et al (2012) Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). J Clin Oncol 30:1620–1627CrossRefPubMedGoogle Scholar
- 7.Fernández-Martos C, Pericay C, Aparicio J et al (2010) Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study. J Clin Oncol 28:859–865CrossRefPubMedGoogle Scholar
- 9.Bujko K, Wyrwicz L, Rutkowski A, et al (2016) Long-course oxaliplatin based preoperative chemoradiation vs. 5 x 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomised phase III study. Ann Oncol 27. doi: 10.1093/annonc/mdw062
- 15.Allegra CJ, Yothers G, O’Connell MJ, et al (2015) Neoadjuvant 5-FU or capecitabine plus radiation with or without oxaliplatin in rectal cancer patients: a phase III randomized clinical trial. J Natl Cancer Inst 107. doi: 10.1093/jnci/djv248
- 18.Resende HM, Jacob LFP, Quinellato LV, Matos D, da Silva EMK (2015) Combination chemotherapy versus single-agent chemotherapy during preoperative chemoradiation for resectable rectal cancer. Cochrane Database Syst Rev 10:CD008531Google Scholar
- 22.Petersen HS, Harling H, Kirkeby LT et al (2012) Postoperative adjuvant chemotherapy in rectal cancer operated for cure. Cochrane Database Syst Rev 3:CD004078Google Scholar
- 24.Hong YS, Nam BH, Kim KP et al (2014) Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. Lancet Oncol 15:1245–1253CrossRefPubMedGoogle Scholar
- 25.Rödel C, Graeven U, Fietkau R et al (2015) Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 16:979–989CrossRefPubMedGoogle Scholar
- 26.Schmoll HJ, Haustermans K, Price TJ et al (2014) Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: first results of the PETACC-6 randomized phase III trial. Proc Am Soc Clin Oncol 32 (abstract 3501)Google Scholar